ALAB
Astera Labs, Inc. Common Stock
ALAB's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over ALAB overall, supported by stronger valuation and lower modeled downside.
ALAB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
ALAB's revenue, profitability, cash flow and balance sheet are all currently strong.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
ALAB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 33x | $228 | — |
| Cheap | 72x | $182 | -20% |
| Current | 91x | $228 | — |
| Fair | 108x | $272 | +19% |
| Expensive | 172x | $431 | +89% |
Historical ranges are pointers, not guarantees.
ALAB's PE is in its fair range at 91x. If earnings grow as analysts expect, today's price would be 33x next year's earnings, in its cheap range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over ALAB in the historical PE scenario, which offers more potential upside but is not a forecast.
ALAB Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| High |
ALAB has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
ALAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.88 | +174% |
| Q3 2026 | $2.51 | +14% |
| Q2 2026 | $2.02 | +22% |
| Q1 2026 | $1.48 | +13% |
| Q4 2025 | $1.22 | +$1.86 |
| Q3 2025 | $2.20 | +$3.98 |
| Q2 2025 | $1.65 | +$3.40 |
| Q1 2025 | $1.31 | +$3.16 |
| Q4 2024 | -$0.64 | -$0.43 |
ALAB earned $2.51 per share over the past year, up 14% from the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over ALAB on earnings, with more consistent year-over-year improvement.
ALAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $584.9M | +154% |
| Q2 2026 | $392.4M | +104% |
| Q1 2026 | $308.4M | +93% |
| Q4 2025 | $270.6M | +92% |
| Q3 2025 | $230.6M | +104% |
| Q2 2025 | $191.9M | +150% |
| Q1 2025 | $159.4M | +144% |
| Q4 2024 | $141.1M | +179% |
ALAB has the edge over NVDA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +6.6 points |
| Q2 2026 | 23% | +2 points |
| Q1 2026 | 20% | +13 points |
| Q4 2025 | 25% | +25 points |
| Q3 2025 | 24% | +32 points |
| Q2 2025 | 21% | +52 points |
| Q1 2025 | 7.1% | +134 points |
| Q4 2024 | 0.1% | -18 points |
ALAB's operating margin was 31% last quarter, up 6.6 points from the same quarter a year ago, near the top of its range since 2022.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA's revenue has grown year over year for 13 quarters in a row: $96.2B last quarter, up 106% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over ALAB on profitability, with a higher operating margin.
ALAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $133.9M | +103% |
| Q2 2026 | $67.2M | -50% |
| Q1 2026 | $67M | +1023% |
| Q4 2025 | $76.6M | +216% |
| Q3 2025 | $65.9M | +41% |
| Q2 2025 | $133.3M | +328% |
| Q1 2025 | $6M | +2516% |
| Q4 2024 | $24.3M | +81% |
ALAB has the edge over NVDA on cash flow, with stronger typical year-over-year growth.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA's free cash flow has been positive every quarter for six years: $127B over the past year, up 76% from the year before.
ALAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +737K shares |
| 1 year | +1.9% | +3.4M shares |
| 3 years | +21% | +31.6M shares |
ALAB has 184M diluted shares, up 1.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $210,000 |
| Q3 2023 | — |
| Q2 2023 | $118,000 |
| Q1 2023 | — |
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over ALAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
ALAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -1.3x | Net Cash |
| Q2 2025 | -3.5x | Net Cash |
ALAB has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
ALAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.1 | Neutral |
| Stochastic | 12.4 | Oversold |
ALAB's weekly RSI is 43 (neutral) and its Stochastic is 12 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
ALAB PE vs Technology Sector
| Metric | ALAB | Sector median | Relative |
|---|---|---|---|
| PE | 91x | 28x | 226% above |
| PE % | 33 | 17 | 16 pts above |
ALAB is trading at 91x earnings, a 226% premium to the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over ALAB on valuation relative to its sector.
ALAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $284.7 | 20% below |
| 20 week MA | $306.9 | 26% below |
| 50 week MA | $241.4 | 5.6% below |
| 100 week MA | $182.7 | 25% above |
ALAB has stronger trend alignment. ALAB is above 1 of 4 weekly averages versus NVDA above 1 of 5.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
ALAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $70.0 | $141.5 | +102% |
| 2025 | $141.5 | $167.3 | +18% |
| 2026 YTD | $167.3 | $227.8 | +36% |
ALAB has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.